论文部分内容阅读
目的探讨肺耐药蛋白(lungresistanceprotein,LRP)与c-erbB-2在上皮性卵巢癌中的表达及其临床意义。方法采用免疫组织化学SP法检测108例上皮性卵巢癌组织和10例正常卵巢组织中LRP和c-erbB-2的表达,并进行相关的临床病理参数分析。结果LRP和c-erbB-2在上皮性卵巢癌中的阳性表达率分别为70.4%和64.8%,而正常卵巢组织中均未见表达,两者表达差异均有显著性(P<0.05)。上皮性卵巢癌组织中LRP的表达与上皮性卵巢癌组织学类型、临床分期、病理分级、患者年龄、残留病灶等临床病理参数无关。c-erbB-2的表达与组织学类型、临床分期、患者年龄和残留病灶无关,与病理分级有关(P<0.05)。LRP表达阳性的卵巢癌患者对化疗的反应率(44.7%)明显低于LRP表达阴性者(93.7%)(P<0.05);c-erbB-2表达阳性的卵巢癌患者对化疗的反应率(42.8%)明显低于c-erbB-2表达阴性者(89.4%)(P<0.05)。结论LRP和c-erbB-2在上皮性卵巢癌中有较恒定的表达,且阳性表达预示化疗反应率低,可能成为预测卵巢癌化疗耐药的指标。
Objective To investigate the expression of lung resistance protein (LRP) and c-erbB-2 in epithelial ovarian cancer and its clinical significance. Methods Immunohistochemical SP method was used to detect the expression of LRP and c-erbB-2 in 108 cases of epithelial ovarian cancer and 10 cases of normal ovarian tissue, and related clinicopathological parameters were analyzed. Results The positive expression rates of LRP and c-erbB-2 in epithelial ovarian cancer were 70.4% and 64.8% respectively, but not in normal ovarian tissues. The difference between them was significant (P <0.05). The expression of LRP in epithelial ovarian cancer has nothing to do with the histological type, clinical stage, histological grade, age of patients, residual lesions and other clinicopathological parameters of epithelial ovarian cancer. The expression of c-erbB-2 was not associated with the histological type, clinical stage, patient’s age and residual disease, but also with pathological grade (P <0.05). The response rate to chemotherapy in ovarian cancer patients with LRP expression was significantly lower than that in patients with LRP negative expression (44.7% vs 93.7%, P <0.05). The response rate to chemotherapy in ovarian cancer patients with positive c-erbB-2 expression 42.8%) were significantly lower than those with negative c-erbB-2 expression (89.4%) (P <0.05). Conclusions LRP and c-erbB-2 are expressed more frequently in epithelial ovarian cancer. The positive expression of LRP and c-erbB-2 may be predictors of chemoresistance in ovarian cancer.